BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...oral), forodesine) fenretinide (4-hpr) Quisinostat (JNJ-26481585) Suberohydroxamic acid phenyl ester (SHAPE), remetinostat (shp-141, SHAPE) lacutamab (IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...data for two compounds, the IgG1 mAb TTI-621...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...data for two compounds, the IgG1 mAb TTI-621...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...million shares at $10.88, which will fund clinical testing of Trillium’s CD47 programs TTI-622 and TTI-621...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...grades of toxicity. Trillium Therapeutics Inc . (TSX:TRIL; NASDAQ:TRIL) data is from IV administration of TTI-621...
...Non-small cell lung cancer (NSCLC) (n=18) 0% 0% 0% 44% Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) TTI-621...
...CD19 , making CD47 blockade dependent on the presence of CD19. 5) Trillium’s lead compound TTI-621...
BioCentury | Jan 5, 2018
Clinical News

Trillium reports Phase I data for TTI-621 in DLBCL

...in the dose-expansion portion of the Phase Ia/Ib TTI-621-01 trial showing that IV TTI-621 (SIRPaFc, SIRPalphaFc...
...led to two complete responses and three partial responses, plus six cases of stable disease. TTI-621...
...decoy receptor to block CD47. Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL), Toronto, Ontario Product: TTI-621 (SIRPaFc, SIRPalphaFc...
BioCentury | Jan 5, 2018
Clinical News

Trillium reports Phase I data for TT-621 in mycosis fungoides

...mycosis fungoides in the Phase I TTI-621-02 trial showing that intratumoral injection of TTI-621 (SIRPaFc, SIRPalphaFc...
...in 9 patients. In three patients with Sézary syndrome, TTI-621 reduced circulating leukemic Sézary cells. TTI-621...
...decoy receptor to block CD47. Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL), Toronto, Ontario Product: TTI-621 (SIRPaFc, SIRPalphaFc...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

...lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) -33% $7.55 TTI-621...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...testing for acute myelogenous leukemia (AML) and solid tumors. Trillium Therapeutics Inc. has TTI-621 (SIRPaFc; SIRPalphaFc...
BioCentury | Apr 25, 2017
Distillery Therapeutics

Cancer

...in additional models of NSCLC. Generic chloroquine is marketed for malaria. Trillium Therapeutics Inc. has SIRPaFc...
Items per page:
1 - 10 of 22